Atualização da Diretriz de Ressuscitação Cardiopulmonar e Cuidados Cardiovasculares de Emergência da Sociedade



Baixar 8.81 Mb.
Pdf preview
Página510/535
Encontro30.06.2021
Tamanho8.81 Mb.
1   ...   506   507   508   509   510   511   512   513   ...   535
638


Atualização
Atualização da Diretriz de Ressuscitação Cardiopulmonar e Cuidados 
Cardiovasculares de Emergência da Sociedade Brasileira de Cardiologia – 2019
Arq Bras Cardiol. 2019; 113(3):449-663
491.  Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay 
JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute 
coronary syndromes. N Engl J Med. 2013;369(11):999-1010.
492.  Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et 
al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. 
Gradient of benefit related to the revascularization strategy. Eur Heart J. 
2002;23(18):1441-8.
493.  Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, et al. 
Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 
1988;319(17):1105-11.
494.  Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin 
versus heparin to prevent myocardial infarction during the acute phase of 
unstable angina. Circulation. 1993;88(5 Pt 1):2045-8.
495.  Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces 
the incidence of myocardial infarction and death in patients with unstable 
angina. A meta-analysis. JAMA. 1996;276(10):811-5.
496.  Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. 
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and 
heparin versus no heparin among 12,490 patients with acute myocardial 
infarction. Lancet. 1990;336(8707):65-71.
497.  Tavazzi L. Heparin in acute myocardial infarction. Haemostasis. 1990;20 
(Suppl 1):122-8.
498.  Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. 
A comparison between heparin and low-dose aspirin as adjunctive 
therapy with tissue plasminogen activator for acute myocardial infarction. 
Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med. 
1990;323(21):1433-7.
499.  Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman 
SL. Effect of heparin on coronary arterial patency after thrombolysis with 
tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 
1990;66(20):1412-7.
500.  Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic 
therapy for acute myocardial infarction. Am J Cardiol. 1991;67(3):3A-11A.
501.  Yamamoto N, Ogawa H, Oshima S, Soejima H, Fujii H, Misumi K, et al. The 
effect of heparin on tissue factor and tissue factor pathway inhibitor in patients 
with acute myocardial infarction. Int J Cardiol. 2000;75(2-3):267-74.
502.  Verheugt FW, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JG. High 
dose bolus heparin as initial therapy before primary angioplasty for acute 
myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot 
study. J Am Coll Cardiol. 1998;31(2):289-93.
503.  Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, 
Goodman SG, et al. Efficacy and safety of the low-molecular weight 
heparin enoxaparin compared with unfractionated heparin across 
the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 
2007;28(17):2077-86.
504.  White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky 
L, et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-
elevation myocardial infarction in elderly and younger patients: results 
from ExTRACT-TIMI 25. Eur Heart J. 2007;28(9):1066-71.
505.  Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-
Sendon J, et al. Enoxaparin is superior to unfractionated heparin in 
patients with ST elevation myocardial infarction undergoing fibrinolysis 
regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart 
J. 2007;28(13):1566-73.
506.  Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, et al. Effect 
of enoxaparin versus unfractionated heparin in diabetic patients with 
ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis 
Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis 
In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J. 
2007;154(6):1078-84.
507.  Lavi S, Cantor WJ, Casanova A, Tan MK, Yan AT, Dzavik V, et al. Efficacy 
and safety of enoxaparin compared with unfractionated heparin in 
the pharmacoinvasive management of acute ST-segment elevation 
myocardial infarction: Insights from the TRANSFER-AMI trial. Am Heart J. 
2012;163(2):176-81.e2.
508.  Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et 
al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-
segment elevation acute coronary syndromes managed with an intended 
early invasive strategy: primary results of the SYNERGY randomized trial. 
JAMA. 2004;292(1):45-54.
509.  Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, et al. 
Efficacy and safety of fondaparinux versus enoxaparin in patients with 
acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors 
or thienopyridines: results from the OASIS 5 (Fifth Organization to 
Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol. 
2009;54(5):468-76.
510.  Fifth Organization to Assess Strategies in Acute Ischemic Syndromes 
Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et 
al. Comparison of fondaparinux and enoxaparin in acute coronary 
syndromes. N Engl J Med. 2006;354(14):1464-76.
511.  Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht HJ, Lopez-Sendon JL, et 
al. Fondaparinux with UnfracTionated heparin during revascularization 
in acute coronary syndromes (FUTURA/OASIS 8): a randomized 
trial of intravenous unfractionated heparin during percutaneous 
coronary intervention in patients with non-ST-segment elevation acute 
coronary syndromes initially treated with fondaparinux. Am Heart J. 
2010;160(6):1029-34.
512.  Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et 
al. Rivaroxaban versus placebo in patients with acute coronary syndromes 
(ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 
2009;374(9683):29-38.
513.  Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban 
with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 
2011;365(8):699-708.
514.  Hoshi T, Sato A, Nogami A, Gosho M, Aonuma K, SAFE-A Investigators. 
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial 
of Apixaban use in association with dual antiplatelet therapy in patients 
with atrial fibrillation undergoing percutaneous coronary intervention. J 
Cardiol. 2017;69(4):648-51.
515.  Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, et al. A 
randomized trial to compare the safety of rivaroxaban vs aspirin in addition 
to either clopidogrel or ticagrelor in acute coronary syndrome: The design 
of the GEMINI-ACS-1 phase II study. Am Heart J. 2016 Apr;174:120-8.
516.  de Kam PJ, Voors AA, van den Berg MP, van Veldhuisen DJ, Brouwer J, Crijns 
HJ, et al. Effect of very early angiotensin-converting enzyme inhibition on 
left ventricular dilation after myocardial infarction in patients receiving 
thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN 
and CATS Investigators. J Am Coll Cardiol. 2000;36(7):2047-53.
517.  O'Connor RE, Bossaert L, Arntz HR, Brooks SC, Diercks D, Feitosa-Filho 
G, et al. Part 9: Acute coronary syndromes: 2010 International Consensus 
on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care 
Science With Treatment Recommendations. Circulation. 2010;122(16 
Suppl 2):S422-65.
518.  Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et 
al. Eplerenone reduces mortality 30 days after randomization following 
acute myocardial infarction in patients with left ventricular systolic 
dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425-31.
519.  Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt 
F, et al. Early eplerenone treatment in patients with acute ST-elevation 
myocardial infarction without heart failure: the Randomized Double-Blind 
Reminder Study. Eur Heart J. 2014;35(34):2295-302.
520.  Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, et 
al. Timing of eplerenone initiation and outcomes in patients with heart 
failure after acute myocardial infarction complicated by left ventricular 
systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 
2009;11(11):1099-105.



Compartilhe com seus amigos:
1   ...   506   507   508   509   510   511   512   513   ...   535


©historiapt.info 2019
enviar mensagem

    Página principal